5-Fluorouracil, Epirubicin, and BCNU (FEB) in Advanced Measurable Gastric Cancer
- 1 June 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (3) , 204-207
- https://doi.org/10.1097/00000421-199006000-00005
Abstract
Forty-eight patients with advanced measurable gastric cancer were treated with the three-drug combination of 5-fluorouracil, epirubicin, and BCNU (FFB). The response rate was 42% in 45 evaluable patients. There were live complete responders (11%). The median duration of response was 1.1 months, and the median survival of all patients was 9.2 months. Toxicity was generally mild to moderate. No instances of congestive heart failure were recorded. These results indicate that patients with metastatic gastric cancer can be effectively palliated with FEB chemotherapy.This publication has 5 references indexed in Scilit:
- An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.Journal of Clinical Oncology, 1986
- Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.Journal of Clinical Oncology, 1986
- A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.Journal of Clinical Oncology, 1985
- Randomized study of combination chemotherapy in unresectable gastric cancerCancer, 1984
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980